Cargando…

Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients

SIMPLE SUMMARY: Non-invasive diagnostic and prognostic biomarkers for urinary bladder cancer (BC) are eagerly awaited, since these could improve patient’s quality of life and reduce resources and costs for the health care system. The PD-1/PD-L1 axis is an important immune escape mechanism for tumors...

Descripción completa

Detalles Bibliográficos
Autores principales: Vikerfors, Anders, Davidsson, Sabina, Frey, Janusz, Jerlström, Tomas, Carlsson, Jessica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616046/
https://www.ncbi.nlm.nih.gov/pubmed/34830993
http://dx.doi.org/10.3390/cancers13225841
_version_ 1784604253223911424
author Vikerfors, Anders
Davidsson, Sabina
Frey, Janusz
Jerlström, Tomas
Carlsson, Jessica
author_facet Vikerfors, Anders
Davidsson, Sabina
Frey, Janusz
Jerlström, Tomas
Carlsson, Jessica
author_sort Vikerfors, Anders
collection PubMed
description SIMPLE SUMMARY: Non-invasive diagnostic and prognostic biomarkers for urinary bladder cancer (BC) are eagerly awaited, since these could improve patient’s quality of life and reduce resources and costs for the health care system. The PD-1/PD-L1 axis is an important immune escape mechanism for tumors, and both high tissue expression and soluble levels of PD-L1 have been shown to be associated with worse prognosis for patients with various tumor. The knowledge about soluble PD-L1 in body fluids such as serum and urine in patients with BC is sparse, and more studies are needed to investigate its role as a biomarker for the disease. In the present study, we show that high serum PD-L1 levels are associated with aggressive disease and development of metastatic disease in BC patients. ABSTRACT: Soluble PD-L1 (sPD-L1) levels have been identified as a potential biomarker for various cancers, but its diagnostic and prognostic value in urinary bladder cancer (BC) remains to be fully elucidated. In this study, we investigated sPD-L1 levels in serum and urine samples from 132 patients with BC and compared them to 51 patients with hematuria (controls). The levels of sPD-L1 in serum and urine were determined using ELISA. Soluble PD-L1 could be detected in 99.5% of the serum samples and 34.4% of the urine samples. Patients diagnosed with BC had significantly higher urinary levels of sPD-L1, compared to controls, however no difference were found in serum sPD-L1 levels (p = 0.038 and p = 0.61, respectively). Significantly higher serum sPD-L1 levels were found in patients with muscle invasive disease and metastatic disease, compared to patients with non-muscle invasive BC and non-metastatic disease (p < 0.05). There was also a trend for higher urine sPD-L1 levels in patients with metastatic disease, compared to patients with non-metastatic disease (p = 0.05). The results from this study suggest that sPD-L1 in serum, but not in urine, could be a potential prognostic biomarker for patients with BC.
format Online
Article
Text
id pubmed-8616046
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86160462021-11-26 Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients Vikerfors, Anders Davidsson, Sabina Frey, Janusz Jerlström, Tomas Carlsson, Jessica Cancers (Basel) Article SIMPLE SUMMARY: Non-invasive diagnostic and prognostic biomarkers for urinary bladder cancer (BC) are eagerly awaited, since these could improve patient’s quality of life and reduce resources and costs for the health care system. The PD-1/PD-L1 axis is an important immune escape mechanism for tumors, and both high tissue expression and soluble levels of PD-L1 have been shown to be associated with worse prognosis for patients with various tumor. The knowledge about soluble PD-L1 in body fluids such as serum and urine in patients with BC is sparse, and more studies are needed to investigate its role as a biomarker for the disease. In the present study, we show that high serum PD-L1 levels are associated with aggressive disease and development of metastatic disease in BC patients. ABSTRACT: Soluble PD-L1 (sPD-L1) levels have been identified as a potential biomarker for various cancers, but its diagnostic and prognostic value in urinary bladder cancer (BC) remains to be fully elucidated. In this study, we investigated sPD-L1 levels in serum and urine samples from 132 patients with BC and compared them to 51 patients with hematuria (controls). The levels of sPD-L1 in serum and urine were determined using ELISA. Soluble PD-L1 could be detected in 99.5% of the serum samples and 34.4% of the urine samples. Patients diagnosed with BC had significantly higher urinary levels of sPD-L1, compared to controls, however no difference were found in serum sPD-L1 levels (p = 0.038 and p = 0.61, respectively). Significantly higher serum sPD-L1 levels were found in patients with muscle invasive disease and metastatic disease, compared to patients with non-muscle invasive BC and non-metastatic disease (p < 0.05). There was also a trend for higher urine sPD-L1 levels in patients with metastatic disease, compared to patients with non-metastatic disease (p = 0.05). The results from this study suggest that sPD-L1 in serum, but not in urine, could be a potential prognostic biomarker for patients with BC. MDPI 2021-11-21 /pmc/articles/PMC8616046/ /pubmed/34830993 http://dx.doi.org/10.3390/cancers13225841 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Vikerfors, Anders
Davidsson, Sabina
Frey, Janusz
Jerlström, Tomas
Carlsson, Jessica
Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients
title Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients
title_full Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients
title_fullStr Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients
title_full_unstemmed Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients
title_short Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients
title_sort soluble pd-l1 in serum and urine in urinary bladder cancer patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616046/
https://www.ncbi.nlm.nih.gov/pubmed/34830993
http://dx.doi.org/10.3390/cancers13225841
work_keys_str_mv AT vikerforsanders solublepdl1inserumandurineinurinarybladdercancerpatients
AT davidssonsabina solublepdl1inserumandurineinurinarybladdercancerpatients
AT freyjanusz solublepdl1inserumandurineinurinarybladdercancerpatients
AT jerlstromtomas solublepdl1inserumandurineinurinarybladdercancerpatients
AT carlssonjessica solublepdl1inserumandurineinurinarybladdercancerpatients